| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BioVie (NASDAQ:BIVI) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.79) by 2...
Each unit is being sold to the public at a price of $2.00 per unit (and each pre-funded unit is being sold to the public at the...